Alterity Therapeutics Files 6-K Report
Ticker: ATHE · Form: 6-K · Filed: Apr 16, 2026 · CIK: 0001131343
Sentiment: neutral
Topics: foreign-issuer, routine-filing, pharmaceuticals
TL;DR
Alterity Therapeutics filed a 6-K, standard foreign issuer report due April 30.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on April 16, 2026, reporting for the period ending April 30, 2026. The filing includes the form itself, an exhibit (EX-99.1), and a graphic image. The company is based in Melbourne, Australia, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides routine updates from a foreign issuer, which may contain important information for investors regarding the company's ongoing operations and financial status.
Risk Assessment
Risk Level: low — A Form 6-K is a routine filing for foreign issuers and typically does not contain significant new material information that would immediately impact risk.
Key Players & Entities
- ALTERITY THERAPEUTICS LTD (company) — Filer
- 0001131343 (company) — CIK
- 2026-04-16 (date) — Filing Date
- 2026-04-30 (date) — Period of Report
- LEVEL 3, 460 BOURKE STREET MELBOURNE Australia (location) — Mailing and Business Address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuer required by SEC rules 13a-16 and 15d-16, used to provide information that the issuer makes or is required to make public in its home country.
When is the period of report for this filing?
The period of report for this filing is 2026-04-30.
What is the CIK number for Alterity Therapeutics Ltd?
The CIK number for Alterity Therapeutics Ltd is 0001131343.
Where is Alterity Therapeutics Ltd located?
Alterity Therapeutics Ltd is located at LEVEL 3, 460 BOURKE STREET MELBOURNE Australia.
What SIC code is associated with Alterity Therapeutics Ltd?
The SIC code associated with Alterity Therapeutics Ltd is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 16, 2026 regarding ALTERITY THERAPEUTICS LTD (ATHE).